UPCC 03419: A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkins Lymphoma
Enrolling By Invitation
99 years or below
All
Phase
2
5 participants needed
1 Location
Brief description of study
This trial is an open-label, multicenter, Phase 1b/2 trial investigating Hu5F9-G4 + rituximab (antibody combination) in R/R B-cell non-Hodgkins lymphoma (NHL) and Hu5F9-G4 + R-GemOx (chemotherapy combination) in indolent lymphoma and diffuse large B cell lymphoma (DLBCL)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Non-Hodgkins Lymphoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832606
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
